Oncology drug development is in a period of unprecedented innovation, driven by growth in the use of targeted therapies and immuno-oncology agents. Biomarkers that reflect the drug target or functional state of the immune system are key in the development process.
As leaders in companion diagnostic development, Covance/LabCorp have supported more than 75 percent of FDA-approved companion diagnostics, including all the current examples of diagnostics used in the area of immuno-oncology. Biomarker approaches that drive the area of precision medicine include:
- Cell-based assays involving flow cytometric evaluation of cell populations or the production of proinflammatory markers
- Tissue based biomarker assays, including immunohistochemistry
- Genomic biomarkers, such as mutational burden and gene expression patterns
This webinar, presented by Chief Scientific Officer at Covance, Steve Anderson, PhD, will address the spectrum of immunotherapy development considerations and their implications for drug developers.
Please join us for an insightful discussion on these clinically and commercially relevant topics.
Steven M. Anderson, PhD, Senior Vice President, Chief Scientific Officer, Covance
Dr. Steven Anderson is the Chief Scientific Officer (CSO) of Covance. In the CSO role, he leads the development and implementation of scientific strategy throughout the various Covance business units, coordinating with the scientific teams in Early Development, Central Labs, Clinical Development, Market Access, and the LabCorp Diagnostics business.
Prior to the CSO role at Covance, Dr. Anderson served in a variety of scientific, technical and operational roles within the LabCorp organization. During his 25 year tenure in LabCorp, these positions included Director of Operations for the Center for Molecular Biology and Pathology (CMBP), Director of Operations for ViroMed Laboratories, Director of Operations for Monogram Biosciences, Director of Operations for Integrated Oncology and Genetics, National Director of Research and Development, and Global Head of LabCorp Clinical Trials.
Dr. Anderson is a member of a variety of professional societies including the American Association for Cancer Research, the American Society of Clinical Oncology and the Association for Molecular Pathology. His research interests are in the development and applications for molecular diagnostics, including several recent examples of companion diagnostics currently in use for patient management.He has authored more than 175 articles and abstracts published in such journals as Genetics, Proceedings of the National Academy of Sciences, Clinical Chemistry, the Journal of Infectious Disease, Human Pathology, American Journal of Obstetrics and Gynecology, Oncogene, the Journal of the National Cancer Institute, Clinical Cancer Research, Breast Cancer Research, BMC Cancer, the Journal of Molecular Diagnostics, Archives of Pathology and Laboratory Investigation and Expert Reviews in Molecular Diagnostics.Dr. Anderson has a PhD in Genetics from Iowa State University, and was an American Cancer Society postdoctoral fellow at the Waksman Institute of Rutgers University.
Who Should Attend?
Chief Medical Officers, Chief Scientific Officers, plus senior level professionals involved in:
◦ Advisor, Oncology Tailoring, Tailored Therapeutics
◦ VP, Molecular Oncology
◦ CDx Scientist
◦ Sr. VP, Biomarker Assay Development
◦ Sr. Director, Clinical Pharmacology
◦ VP, Translational Immunology
- Medical Affairs / Regulatory Affairs
- Regulatory Strategy
- Translational Medicine
- Personalized Medicine
- Biomarker Development
- Companion Diagnostic Strategy
- Preclinical or Clinical Outsourcing
Covance is one of the world’s largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion and more than 12,000 employees in more than 60 countries.
Sign Up To Register for this Webinar
Interested in this webinar? Signup to learn more and register for upcoming webinars or recorded webinars.Sign Up